Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib

doi:10.4254/wjh.v14.i7.1438

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3754)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

187

WORD

HTML

2149

Figures (1-1)

299

Tables (1-5)

298

Sum=2973

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

253

Download

528

Sum=781

Jul 27, 2022 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Hepatol. Jul 27, 2022; 14(7): 1438-1458
Published online Jul 27, 2022. doi: 10.4254/wjh.v14.i7.1438

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flowchart.

Citation: Sapena V, Iavarone M, Boix L, Facchetti F, Guarino M, Sanduzzi Zamparelli M, Granito A, Samper E, Scartozzi M, Corominas J, Marisi G, Díaz A, Casadei-Gardini A, Gramantieri L, Lampertico P, Morisco F, Torres F, Bruix J, Reig M. Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib. World J Hepatol 2022; 14(7): 1438-1458
URL: https://www.wjgnet.com/1948-5182/full/v14/i7/1438.htm
DOI: https://dx.doi.org/10.4254/wjh.v14.i7.1438